New hope for psoriasis patients when first treatment fails
NCT ID NCT06945107
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called picankibart for people with plaque psoriasis who did not improve enough after using standard IL-17 antibody treatments. About 308 adults in China will take part. The goal is to see if switching to picankibart can clear or nearly clear the skin better than continuing current treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dermatology Hospital of Shandong First Medical University (Shandong Provincial Hospitial of Dermatology)
Jinan, Shandong, 250000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New oral pill TLL018 aims to clear psoriasis plaques in phase 2 trial
- Psoriasis drug may be safe for patients with fatty liver
- New cream shows promise for clearing psoriasis in chinese patients
- Could a simple skincare routine soothe psoriasis Flare-Ups?
- New psoriasis cream shows early promise in small trial
- New biologic drug netakimab tested in kids with psoriasis